ClinicalTrials.gg
CompletedNCT03160105Simpl'HIVUpdated Aug 29, 2019

Evaluation of a Simplified Strategy for the Long-term Management of HIV Infection (Simpl'HIV)

A Phase 4 interventional study of Switch to DTG + FTC and Patient-centered monitoring in HIV-1-infection, Antiretroviral Therapy and Maintenance Therapy, sponsored by Calmy Alexandra. Completed at 7 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-29.

Sponsored by Calmy Alexandra · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate whether maintenance antiretroviral therapy could be simplified to DTG + FTC dual therapy and/or patient-centered monitoring once virological suppression is achieved. Using a factorial design, the study aims to assess the efficacy of DTG + FTC dual therapy to maintain virological suppression through 48 weeks of follow-up as well as the costs of a patient-centered ART laboratory monitoring.

Read the detailed description

This is a pragmatic multicentre, 2x2 factorial randomized controlled trial with 1:1:1:1 randomization to switching to DTG-based maintenance dual therapy in association with FTC or continuation of cART, and to patient-centered monitoring or continuation of standard monitoring.

Patients will be followed during 48 weeks.

02

Conditions studied

  • HIV-1-infection
  • Antiretroviral Therapy
  • Maintenance Therapy
03

In context

Lead sponsor

Calmy Alexandra is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. as documented by signature;
  2. Documented -1 infection;
  3. Enrolled in the Swiss HIV Cohorte Study (SHCS) or receiving care from a medical doctor of the SHCS network;
  4. ≥ 18 years of age;
  5. HIV-RNA \<50 copies/mL at screening and for at least 24 weeks before screening on effective suppressive cART, one blip with less than 200 copies/mL being allowed during this period if followed by at least 2 results \< 50 copies/mL.
  6. On standard cART at the time of inclusion, i.e.:

    • 2 NRTIs + either 1 NNRTI, 1 boosted PI or 1 INSTI;
    • NRTI-sparing triple ARV regimen (e.g. 1 NRTI + 1 NNRTI + 1 InSTI);
    • Dual therapy with protease inhibitor.

Exclusion criteria

Exclusion Criteria:

  1. -2 infection;
  2. Previous ART change for unsatisfactory virological response, i.e. slow initial virological suppression, incomplete suppression or rebound. Change of drug or drug class for convenience or toxic effect prevention or management is allowed.

    Note: patients with documented genotype(s) presenting only a M184V mutation remain eligible;

  3. \< 50ml/min;
  4. ASAT or ALAT >2.5x upper limit of the norm;
  5. Known , intolerance or allergy to DTG or FTC;
  6. Known or suspected non-adherence (defined as \<80% adherence, i.e. missed doses > 1x/week) to current treatment in the last 6 months;
  7. Concomitant use of drugs that decrease DTG blood concentrations including carbamazepine, oxcarbamazepine, phenytoin, phenobarbital, St John's wort and rifampicin;
  8. Women who are pregnant or breast-feeding;
  9. a. Presence of any INSTI-resistance. Non-availability of INSTI resistance testing is NOT an exclusion criteria.

    b. Non availability of previous routine resistance test, at least for reverse transcriptase and protease genes.

    Note: Subjects remain eligible in the absence of any previous resistance test only if they are on their antiretroviral regimen;

  10. Evidence of acute or chronic virus infection based on results of serology testing.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
186 participants (actual)

Study arms

  • No intervention
    Continuing cART + Standard monitoring

    Patients randomized to this arm will continue their current standard ART regimen (cART) and will continue a standard 3-monthly routine safety biological monitoring (including CD4 cell count, fasting lipids and glucose, renal and hepatic function tests) at their SHCS site.

  • Experimental
    Continuing cART + Patient-centered monitoring

    Patients randomized to this arm will continue their current cART and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36

    Other: Patient-centered monitoring

  • Experimental
    Switch to DTG+FTC + Standard monitoring

    Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36

    Drug: Switch to DTG + FTC

  • Experimental
    Switch to DTG+FTC + Patient-centered monitoring

    Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed at screening and at week 48. In addition, patients will be ask to choose at least one of the following alternative options for weeks 6, 12 and 36: decentralised venipuncture and blood tests, delivery of ARV drugs by mail and Assessment and clinical interview by phone or skype call

    Drug: Switch to DTG + FTC · Other: Patient-centered monitoring

Interventions

  • DrugSwitch to DTG + FTC

    Switch from standard cART to DTG + FTC dual maintenance therapy.

  • OtherPatient-centered monitoring

    Immunological and safety blood examinations performed only once per year at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36

06

What researchers measure

Primary outcomes

  1. Efficacy of DTG-based maintenance therapy (< 100 copies/ml)

    Proportion of patients maintaining HIV-RNA \<100 copies/ml throughout 48 weeks

    Time frame: 48 weeks

  2. Costs of a patient-centered ART monitoring

    Direct costs of the two study arms from the health care system perspective at week 48

    Time frame: 48 weeks

Secondary outcomes

  1. Efficacy of DTG-based maintenance therapy (<50 copies/ml)

    Proportion of patients maintaining HIV-RNA \<50 copies/ml throughout 48 weeks

    Time frame: 48 weeks

  2. Efficacy of DTG-based therapy (<50 copies/ml) by FDA snapshot analysis

    Proportion of patients with HIV-RNA \< 50 cp/ml at week 48

    Time frame: 48 weeks

  3. HIV-RNA >100 copies/ml as time to loss of virological response (TLOVR)

    defined as the first of the two-confirmed HIV-RNA \>100 copies/ml (at least two weeks apart)

    Time frame: 48 weeks

  4. Change in CD4 cell count

    from baseline to week 48

    Time frame: 48 weeks

  5. Change in HIV-DNA

    from baseline to week 48

    Time frame: 48 weeks

  6. Change in lipidic profile

    from baseline to week 48

    Time frame: 48 weeks

  7. Change in glucose profile

    from baseline to week 48

    Time frame: 48 weeks

  8. Change in Framingham-calculated cardiovascular risk

    from baseline to week 48

    Time frame: 48 weeks

  9. Change in glomerular function rate

    from baseline to week 48

    Time frame: 48 weeks

  10. Proportion of patients with an adverse event

    throughout week 48

    Time frame: 48 weeks

  11. Proportion of patients with a severe adverse event

    throughout week 48

    Time frame: 48 weeks

  12. Proportion of patients with CNS adverse event

    throughout week 48

    Time frame: 48 weeks

  13. Proportion of patients new to DTG with CNS symptoms

    at 2 and 6 week

    Time frame: 6 weeks

  14. PROQOL questionnaire

    from baseline to weeks 12 and 48

    Time frame: 48 weeks

  15. Patient's monitoring satisfaction for pts in the patient-centered monitoring arm

    from baseline to weeks 24 and 48

    Time frame: 48 weeks

  16. Global satisfaction of the monitoring

    at week 48

    Time frame: 48 weeks

  17. Proportion of patients in the patient-centered monitoring arm expressing willingness to change monitoring options

    Monitoring satisfaction throughout 48 weeks

    Time frame: 48 weeks

  18. Patient's treatment satisfaction at week 48

    at week 48

    Time frame: 48 weeks

  19. ARV treatment in the post study

    ART decided to be used in the post study period

    Time frame: 48 weeks

  20. Study satisfaction

    at week 48

    Time frame: 48 weeks

  21. Cost-effectiveness of study arms

    at week 48

    Time frame: 48 weeks

  22. Change in patient weight

    from baseline to week 48

    Time frame: 48 weeks

  23. Adherence questions

    Patient adherence to treatment throughout 48 weeks of follow-up

    Time frame: 48 weeks

  24. Number of study-related extra clinical visits

    performed outside trial scheduled throughout 48 weeks

    Time frame: 48 weeks

07

Study locations

7 sites
  • Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Basel
    Basel, Switzerland
  • Departement of Infectious Disease, Bern University Hospital
    Bern, Switzerland
  • Infectious diseases consultation, University Hospitals of Geneva
    Genève, Switzerland
  • Infectious Diseases Service, Lausanne University Hospital
    Lausanne, Switzerland
  • Department of Infectious Diseases, Lugano Regional Hospital
    Lugano, Switzerland
  • Division of Infectious Diseases and Hospital Epidemiology, Kantonspital St.Gallen
    St. Gallen, Switzerland
  • Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich
    Zürich, Switzerland
08

References and documents

Publications

  • Sculier D, Wandeler G, Yerly S, Marinosci A, Stoeckle M, Bernasconi E, Braun DL, Vernazza P, Cavassini M, Buzzi M, Metzner KJ, Decosterd LA, Gunthard HF, Schmid P, Limacher A, Egger M, Calmy A; Swiss HIV Cohort Study (SHCS). Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial. PLoS Med. 2020 Nov 10;17(11):e1003421. doi: 10.1371/journal.pmed.1003421. eCollection 2020 Nov. PubMed 33170863 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in Apr 2018, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2017
First posted
May 19, 2017
StartActual
May 19, 2017
Primary completionActual
Apr 18, 2018
CompletionActual
May 20, 2019
Last update
Aug 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03160105
Lead sponsor
Calmy Alexandra
Responsible party
Calmy Alexandra (Professor, University Hospital, Geneva) — Sponsor-investigator
First posted
May 19, 2017
Start date
May 19, 2017
Primary completion
Apr 18, 2018
Completion
May 20, 2019
Last update
Aug 29, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion